EBS Emergent Biosolutions, Inc. Com

29.84
+1  (3%)
Previous Close 28.99
Open 29.16
Price To book 1.97
Market Cap 1.21B
Shares 40,687,000
Volume 298,041
Short Ratio 9.94
Av. Daily Volume 318,302

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease

Latest News

  1. Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : April 26, 2017
  2. Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017
  3. Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin
  4. Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : March 20, 2017
  5. Emergent BioSolutions gets $100 million anthrax contract from feds
  6. Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile
  7. Local drug company stocks react to Trump's proposed cuts to NIH, FDA
  8. Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner Gilead Sciences
  9. Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : March 9, 2017
  10. Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
  11. Emergent BioSolutions Inc Sets its Goal
  12. Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
  13. Edited Transcript of EBS earnings conference call or presentation 23-Feb-17 10:00pm GMT
  14. Emergent Biosolutions posts 4Q profit
  15. Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals
  16. Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics
  17. Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017
  18. Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue
  19. Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax
  20. 3 Cheap Growth Stocks You Can Buy Right Now